Prevalence of Atrophic Gastritis in Southwest China and Predictive Strength of Serum Gastrin-17: A Cross-sectional Study (SIGES)
Authors
Affiliations
A hospital-based cross-sectional study in SIGES project was conducted during 2016.5-2017.5 in West China Hospital. It was aimed to observe the prevalence of atrophic gastritis (AG) in southwest China, and assess the diagnostic strength of serum gastrin-17 (G-17) in predicting AG in Chinese population. Asymptomatic healthy controls from health check-up, cancer-free patients with unspecific upper gastrointestinal symptoms, and histologically proven gastric cancer patients were eligible, if serum pepsinogen-I (PG-I), PG-II, and G-17 were detected. AG status was classified by the accredited cutoffs of PG-I (<70 ug/L) and PG-I/II ratio (<3). Totally, healthy controls (n = 9,425), symptomatic patients (n = 671) and gastric cancer patients (n = 305) were simultaneously observed, in which the prevalence of AG in southwest China were estimated as 15.9/1,000, 28.3/1,000, and 55.7/1,000 persons, respectively. The age-specific prevalence of AG in healthy controls showed a significantly uphill trend (p for trend <0.001). Higher level of serum G-17 was significantly associated with increased risk of AG in healthy population (15-30 pmol/L, aOR = 20.67, 95% CI 9.17-46.55; >30 pmol/L, aOR = 314.41, 95% CI 166.10-595.12). Throughout the progression of stomach diseases, the diagnostic strength of serum G-17 for AG showed a downhill trend across more advanced situations. In despite of that, serum G-17 displayed a good performance in predicting AG in the entire cross-sectional population (AUC = 0.92, 95% CI 0.89-0.94; SEN = 85.5%; SPE = 93.2%; LR+ = 12.55; LR- = 0.11). Population in southwest China had intermediate prevalence of AG, while the prevalence was increased over age or disease progression. High level of serum G-17 might be a reliable non-invasive measurement to predict AG in southwest Chinese population.
Pei B, Sun Q, Zhang Y, Wen Z, Ding W, Wu K BMC Cancer. 2025; 25(1):63.
PMID: 39794766 PMC: 11720569. DOI: 10.1186/s12885-024-13394-0.
Global progress and future prospects of early gastric cancer screening.
Huang Y, Shao Y, Yu X, Chen C, Guo J, Ye G J Cancer. 2024; 15(10):3045-3064.
PMID: 38706913 PMC: 11064266. DOI: 10.7150/jca.95311.
Zou J, Wen M, Huang Y, Chen X, Hu J Front Public Health. 2023; 11:1128765.
PMID: 38089026 PMC: 10711608. DOI: 10.3389/fpubh.2023.1128765.
Analysis of gastrin-17 and its related influencing factors in physical examination results.
Zeng J, Shen Y, Xu S, Yang R Immun Inflamm Dis. 2023; 11(10):e993.
PMID: 37904688 PMC: 10604568. DOI: 10.1002/iid3.993.
Sharma P, Phatak S, Warikoo P, Mathur A, Mahant S, Das K 3 Biotech. 2023; 13(9):303.
PMID: 37588796 PMC: 10425313. DOI: 10.1007/s13205-023-03734-5.